Antibiotic Resistances of Enterobacteriaceae with Chromosomal Ampc in Urine Cultures: Review and Experience of a Spanish Hospital
Metadatos
Mostrar el registro completo del ítemAutor
Rodríguez Guerrero, Enrique; Requena Cabello, Horacio; Expósito Ruiz, Manuela; Navarro Marí, José María; Gutiérrez Fernández, JoséEditorial
MDPI
Materia
Antibiotic resistances Urinary tract infections Chromosomal AmpC beta-lactamases Enterobacteriaceae
Fecha
2023-04-08Referencia bibliográfica
Rodríguez-Guerrero, E.; Cabello, H.R.; Expósito-Ruiz, M.; Navarro-Marí, J.M.; Gutiérrez-Fernández, J. Antibiotic Resistances of Enterobacteriaceae with Chromosomal Ampc in Urine Cultures: Review and Experience of a Spanish Hospital. Antibiotics 2023, 12, 730. [https://doi.org/10.3390/ antibiotics12040730]
Resumen
The Enterobacteriaceae Citrobacter freundii, Enterobacter cloacae, Klebsiella aerogenes, Morganella
morganii, Providencia stuartii, and Serratia marcescens (CESPM group) produce numerous
urinary tract infections (UTIs) which are difficult to treat due to their high multiresistance rate. The
objectives of this study were to carry out a systematic review of antibiotic resistances by UTIs and
to determine changes over time in urine cultures from a reference hospital in southern Spain. The
literature was searched for European data on the resistance rates of each microorganism, and a
retrospective cross-sectional descriptive study was performed in samples with suspicion of UTI
from patients in Virgen de las Nieves University Hospital (Granada, Spain) between 2016 and the
first half of 2021. Among 21,838 positive urine cultures, 1.85% were caused by E. cloacae, 0.77%
by M. Morganii, 0.65% by K. aerogenes, 0.46% by C. freundii, 0.29% by P stuartii, and 0.25% by
S. marcescens. The lowest resistance rates by microorganism were: E. cloacae to amikacin (3.47%) and
imipenem (5.28%); M. morganii to piperacillin–tazobactam (1.79%), cefepime (4.76%), and tobramycin
(7.74%); K. aerogenes to tobramycin (3.55%), gentamicin (4.25%), trimethoprim–sulfamethoxazole
(4.96%), imipenem (5.75%), and cefepime (6.43%); C. freundii to imipenem (no resistance), nitrofurantoin
(1.96%), fosfomycin (2.80%), and ertapenem (6.12%); P. stuartii to cefepime (3.28%) and
ceftazidime (3.28%); and S. marcescens to gentamicin (1.8%), ciprofloxacin (3.64%), cefepime (3.70%),
piperacillin–tazobactam (3.70%), and trimethoprim–sulfamethoxazole (5.45%). In our setting, CESMP
Enterobacteriaceae showed the lowest resistance to piperacillin–tazobactam, cefepime, imipenem,
gentamicin, and colistin, which can therefore be recommended for the empirical treatment of UTIs.
The COVID-19 pandemic may have had a clinical impact in relation to the increased resistance of E.
cloacae and M. morgani to some antibiotics.